** Shares of drugmaker Pfizer PFE.N rise ~2% to $26.72 premarket
** Co reports Q4 adj. profit of 63 cents per share, above analysts' est. of 47 cents, according to data compiled by LSEG, driven by strong sales of its heart disease drug and COVID-19 vaccine sales
** Co posts Q4 sales of $17.76 bln vs analysts' est. of $17.36 bln - LSEG
** Q4 sales of heart disease drug, sold as Vyndaqel and Vyndamax, came in at $1.55 bln, above estimates of $1.48 bln - LSEG
** COVID vaccine Comirnaty brought in sales of $3.38 bln, above analysts' est. of $3.10 bln - LSEG
** PFE fell 10.8% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.